Hormones are specialized mitogens that stimulate proliferation in their dierentiated target cells. Thyrotropin (TSH), the physiologic regulator of thyroid cells, stimulates cAMP-mediated proliferation and thyroidspeci®c gene expression. The mitogenic eects of TSH require Ras, therefore Ras activation should be compatible with the maintenance of thyroid dierentiation. However, expression of activated Ras extinguishes the dierentiated phenotype of thyroid cells. One explanation for this apparent paradox is the selective utilization of Ras eector pathways. We tested the hypothesis that Ras signaling through PI3K mediates the mitogenic eects of TSH in cells which retain their dierentiated character. Expression of a Ras eector mutant (RasV12S35) that signals preferentially through Raf-1, although sucient to confer TSH-independent proliferation, abolished hormone-regulated expression of thyroglobulin and the sodium/iodide symporter. In contrast, expression of a Ras mutant (RasV12C40) that binds selectively to PI3K conferred TSH-independent proliferation without marked eects on thyroid-speci®c gene expression. Unlike the inhibitory eects of TSH on the proliferation of RasV12S35-expressing cells, TSH enhanced RasV12C40-stimulated proliferation by further increasing the activity of p70s6k, an important mediator of the mitogenic eects of TSH and RasV12C40. These results demonstrate that channeling Ras-dependent signals to PI3K confers TSH with the ability to stimulate proliferation in dierentiated cells. Oncogene (2000) 19, 924 ± 932.
Introduction
Thyroid follicular cells are dierentiated epithelial cells specialized to synthesize and secrete thyroid hormones. TSH stimulates the expression of thyroid-speci®c genes and proliferation through cAMP-mediated signaling pathways. In Wistar rat thyroid (WRT) cells, the mitogenic activity of TSH is Ras-dependent, and the requirement for Ras maps downstream from cAMP (Kupperman et al., 1993) . Expression of oncogenic Hor K-Ras in thyroid cells confers TSH-independent proliferation (Fusco et al., 1987; Lemoine et al., 1990; Meinkoth et al., 1991) , and mutations in all three cellular Ras genes have been identi®ed in human thyroid tumors (Fagin, 1994) . While Ras stimulates thyroid cell proliferation, Ras transformation leads to decreased expression and/or activity of the transcription factors TTF-1 and TTF-2, resulting in the loss of thyroid-speci®c gene expression (Fusco et al., 1987; Avvedimento et al., 1989; Francis-Lang et al., 1992) . Nonetheless, Ras mutations are found in hyperfunctioning adenomas and in dierentiated follicular and papillary carcinomas (Wynford-Thomas, 1997), evidence that expression of activated Ras is not invariably associated with thyroid de-dierentiation.
Ras activates multiple downstream pathways (White et al., 1995) including Raf-1 and the MAPK cascade (Marias and Marshall, 1996) , RalGDS and Ral proteins (Feig et al., 1996) , and PI3K (Downward, 1997) and Rac1 (Qiu et al., 1995; Khosravi-Far et al., 1995) . Alterations in the balance of the activity of these pathways may contribute to the dierential cellular responses elicited by Ras. Multiple Ras-dependent pathways converge in the regulation of dierentiation and cell cycle arrest in PC12 cells, where the eects of Ras on neurite extension and growth arrest are mimicked by Raf-1 and PI3K, while RalGDS inhibits withdrawal from the cell cycle (Goi et al., 1999) . In thyroid cells, cAMP impairs Ras signaling through Raf-1 (Al-Alawi et al., 1995) and augments Ras signaling through RalGDS (Miller et al., 1998) . In addition, cAMP activates and requires PI3K-dependent signals for its mitogenic eects (Cass et al., 1999) . The ability of TSH to in¯uence the eector pathways activated by Ras may be crucial for its ability to stimulate proliferation and dierentiation. Consistent with this idea, we demonstrate that Ras-mediated activation of PI3K confers hormone-independent proliferation without impairing TSH-regulated dierentiation.
Results

RasC40 confers hormone-independent proliferation
TSH-stimulated proliferation is Ras- (Kupperman et al., 1993) and PI3K (Cass et al., 1999) dependent. Based on this, we examined whether Ras-mediated activation of PI3K was sucient to stimulate TSHindependent proliferation. Thyroid cells stably expressing RasV12C40 (referred to as RasC40 cells), a mutant that binds preferentially to PI3K (RodriguezViciana et al., 1997) , were isolated. RasC40 expression was documented by immunoblotting with an antibody recognizing the HA epitope tag. The levels of RasC40 expression relative to cellular Ras, as determined by immunoblotting with anti-Ras antibodies, ranged from 3 ± 30-fold. Several clones were analysed in detail and yielded similar results. The results obtained using clone B3, which expressed RasV12C40 at levels threefold higher than cellular Ras, are presented ( Figure 1a) .
The second messengers activated by RasC40 in thyroid cells were identi®ed by monitoring kinase activities in the absence of growth factors. Compared to vector-transfected cells, cells expressing RasC40 exhibited constitutively elevated levels of activated Akt, as assessed by increased phosphorylation at Ser473 (Alessi and Cohen, 1998) (Figure 1b) . Increased levels of phosphorylated S6 protein, the physiological substrate of p70s6k (Pullen and Thomas, 1997) , were also observed in these cells (Figure 1b) . Consistently, the electrophoretic mobility of p70s6k was retarded in RasC40 cells, indicative of hyperphosphorylation and activation. Wortmannin reduced both Akt and p70s6k activity, indicating that RasC40 activates Akt and p70s6k through PI3K. Activation of p70s6k, but not Akt, was blocked by rapamycin, an inhibitor of mTOR that prevents p70s6k activation (Dumont and Su, 1996) . Treatment with the MEK inhibitor, PD98059, had no eect on Akt or p70s6k activity. To address the possibility that overexpression of RasC40 abolished the speci®city of its eector interactions, MAPK activity was examined. Although MAPK was constitutively activated in cells expressing RasV12S35 (referred to as RasS35 cells (Miller et al., 1998) , a mutant that selectively binds to Raf-1, phosphorylated MAPK was not detected in RasC40 cells (Figure 1c) . These results indicate that the speci®city of RasC40 is maintained despite its threefold overexpression relative to cellular Ras.
Compared to vector-transfected control cells, DNA synthesis was consistently elevated in RasC40 cells in the absence of TSH (Figure 2a ). Wortmannin and rapamycin abolished DNA synthesis, indicating a requirement for PI3K and mTOR/p70s6k in cell cycle progression. In contrast, the MEK inhibitor PD98059 had no eect on DNA synthesis. Conversely, PD98059, but not wortmannin or rapamycin, inhibited DNA synthesis in RasV12S35-expressing cells (Figure 2a ). These results demonstrate that expression of RasC40 is sucient to confer TSH-independent proliferation, and that mitogenic signaling in RasC40 cells requires PI3K and p70s6k, but not MEK activity. This inhibitor pro®le is similar to that of TSH in parental WRT cells where PI3K (Cass et al., 1999) and p70s6k (Cass and Meinkoth, 1998) , but not Raf-1 or Mek (Al-Alawi et al., 1995) , are required for hormone-stimulated proliferation.
Ras-transformed cells can secrete a variety of growth factors, including those that can contribute to the activation of PI3K and its downstream targets . Therefore we examined whether acute expression of RasV12C40 was sucient to activate p70s6k and stimulate DNA synthesis. Microinjection of puri®ed RasV12C40 protein into quiescent WRT cells induced S6 phosphorylation, a marker of p70s6k activity (Figure 2c ). Microinjection of RasV12C40 protein also stimulated DNA synthesis in a dosedependent manner (Figure 2b ). Rapamycin abolished both p70s6k activity and DNA synthesis (Figure 2c and data not shown), similar to the eects observed in cells stably expressing RasC40.
TSH does not impair RasC40-stimulated DNA synthesis
The growth rate of thyroid cells expressing RasV12S35 is reduced in the presence of TSH, an eect that appears to be mediated by inhibitory eects of PKA on RasS35-stimulated MAPK activity (Miller et al., 1998) . Given that the mitogenic eects of TSH require PI3K activity, we speculated that TSH would not impair RasC40-stimulated proliferation. Indeed, treatment with TSH, or several independently-acting cAMP elevating agents, failed to decrease DNA synthesis in RasC40 cells ( Figure   Figure 1 Akt and p70s6k activity are elevated in RasC40-expressing cells. (a) Lysates from WRT (C; 100 mg) and RasC40 B3 cells (50 mg) were analysed by immunoblotting with antibodies to HA and Ras. Densitometry revealed that RasC40 was overexpressed threefold relative to endogenous c-Ras. Transgene expession was detected in 11 RasC40 cell lines analysed, and varied in expression from 3 ± 30-fold over c-Ras. (b) RasC40 B3 cells were transfected to basal medium for 24 h and Akt and p70s6k activity were monitored in the same cell lysates in the absence of inhibitors (None) or following 2 h treatment with wortmannin (Wm; 200 nM), rapamycin (Rap; 1 nM), or PD98059 (PD; 25 mM). Quiescent vector-transfected cells (C) were included as a control. Lysates were analysed by immunoblotting with phospho-speci®c antibodies to Akt1 (Akt-P) or S6 (S6-P), or with a polyclonal antibody to p70s6k, which also provides an internal control for protein loading. The p70aII (bottom panel) and p85aI (not shown) isoforms of p70s6k exhibited similar electrophoretic mobility shifts under each condition. Similar results were obtained in four experiments in RasC40 B3 cells, and in a total of 12 experiments in ®ve independent RasC40 cell lines. (c) Lysates prepared from RasC40 B3 cells incubated in basal medium for 24 h (used above for S6-P, Akt-P) were analysed by immunoblotting with a phospho-speci®c MAPK antibody. Vector-transfected (C) and RasS35 cells were included as negative and positive controls, respectively. Similar results were obtained in three experiments in RasC40 B3 cells, and in a total of eight experiments in ®ve independent RasC40 cell lines. MAPK phosphorylation was observed in three independent RasS35 cell lines 3a), eects very dierent from those observed in RasS35 cells (Miller et al., 1998) . Indeed, cAMP elevating agents modestly, but consistently enhanced DNA synthesis in RasC40 cells. To elucidate the mechanism behind this eect, the eects of TSH on second messenger activation in RasC40 cells were examined. In parental cells, TSH signaling diverges to include a PI3K-dependent pathway to Akt and a PI3K-independent pathway to p70s6k (Cass et al., 1999) . Consistent with these observations, TSH ( Figure 3b ) or 8BrcAMP (data not shown) failed to further stimulate Akt phosphorylation in RasC40 cells. However, these cAMP elevating agents markedly increased S6 phosphorylation in RasC40 cells with kinetics similar to those observed in parental cells (Cass and Meinkoth, 1998) . Wortmannin had no eect on TSH-stimulated S6 phosphorylation (Figure 3c ), unlike its eects on basal levels of S6 phosphorylation in RasC40 cells (Figure 1b) . In contrast, the PKA-speci®c inhibitor H89 abolished TSH-stimulated S6 phosphorylation (Figure 3c ), as reported for parental cells (Cass et al., 1999) . These ®ndings indicate that TSH and RasC40 regulate p70s6k activity through distinct signaling pathways. TSH stimulates p70s6k through a PKA-dependent, but PI3K-independent pathway, while RasC40-stimulated p70s6k activity is PI3K-dependent. In contrast, TSH (Cass et al., 1999) and RasC40 ( Figure  1b) both activate Akt by a PI3K-dependent mechanism. Based on these results, we expected that activation of p70s6k by TSH would be Ras-independent.
To investigate whether Ras was required for TSHstimulated p70s6k activity, parental WRT cells were infected with an adenovirus encoding RasN17. Expression of RasN17 did not impair S6 phosphorylation stimulated by TSH (Figure 4 ) or forskolin (data not shown), although it abolished IGF-1-stimulated MAPK activity (Figure 4 ). This eect was speci®c to RasN17, since infection with an adenovirus encoding b-galactosidase had no eect on MAPK phosphorylation (data not shown). To further document that the eects of TSH on p70s6k were Ras-independent, acute microinjection experiments were performed. Injection of GST-RalGDS-RBD, a peptide that sequesters GTPbound Ras, did not impair TSH-stimulated S6 phosphorylation, although it repressed DNA synthesis as previously reported (Miller et al., 1997) (Table 1) . Therefore, in striking contrast to the inhibitory eects of TSH on RasS35-stimulated MAPK activity and proliferation, these data demonstrate that not only does TSH fail to interfere with Ras signaling through PI3K, as evidenced by its lack of an inhibitory eect on RasC40-stimulated Akt or p70s6k activity, but that TSH and RasC40 collaborate to stimulate proliferation through dierential regulation of p70s6k.
Expression of RasC40 is compatible with thyroid differentiation
The ability of TSH to stimulate Tg expression in RasC40 cells was analysed to determine whether RasC40 expression was accompanied by de-dierentiation. Following incubation in TSH-de®cient medium for 10 days, Tg expression was undetectable by RasC40 B3 cells were transferred to basal medium for 24 h and treated with TSH (1 mU/ml) for 0, 2, 5, 15, 30, or 60 min. The same lysates were analysed by immunoblotting with phosphospeci®c antibodies to Akt1 (Akt-P) and S6 (S6-P). Quiescent vector-transfected cells (C) were included as a control. Similar results were obtained in ®ve experiments in RasC40 B3 cells, and in four experiments in RasC40 P6 cells. (c) RasC40 B3 cells were transfected to basal medium for 24 h and treated with TSH for 45 min in the absence (7) or presence of wortmannin (Wm; 200 nM) or H89 (25 mM). Although without eect on TSHstimulated S6-P, Wm at the same concentration impaired both Akt-P and S6-P in RasC40 cells in basal medium, documenting that it inhibits basal levels of PI3K activity under these conditions. Untreated RasC40 cells (0) are included as controls. Similar results were obtained in 3 ± 5 experiments Figure 4 TSH-stimulated p70s6k activity is Ras-independent. WRT cells incubated in basal medium for 48 h were treated for 45 min with TSH (1 mU/ml) or for 5 min with IFG-I (200 ng/ml) in the absence (7) or presence (+) of infection with AdN17Ras (m.o.i.=25). Untreated WRT cells (C) were included as controls. Lysates were analysed by immunoblotting with anti-Ras antibodies (N17Ras) and phospho-speci®c antibodies to S6 (S6-P) and MAPK (MAPK-P). Similar results were obtained in four experiments immunostaining (Figure 5a) or immunoblotting (Figure 5b) . TSH stimulated Tg expression to similar levels in RasC40 cells as it did in vector-transfected control cells. Similarly, Tg expression was comparable in exponentially growing RasC40 and parental cells (data not shown). In contrast, as previously reported (Miller et al., 1998) , TSH failed to stimulate Tg expression in RasS35 cells (Figure 5b ). The absence of Tg expression in these cells was not due to alterations in the kinetics of Tg expression, as treatment with TSH for times ranging from 24 ± 72 h failed to induce Tg expression (data not shown). We noted, however, that RasS35 was overexpressed by 30-fold, signi®-cantly higher than the threefold levels of RasC40 overexpression. Therefore, to preclude the possibility that higher levels of RasC40 expression might also impair dierentiation, Tg expression was examined in cells where RasC40 was overexpressed 30-fold relative to cellular Ras. Even when overexpressed at these high levels, RasC40 failed to inhibit TSH-stimulated Tg expression (Figure 5b ).
To corroborate these ®ndings, the eects of RasC40 and RasS35 on expression of the sodium iodide symporter (NIS) (Dai et al., 1996) were compared. NIS expression, which was undetectable in membrane fractions prepared from quiescent cells, was signi®cantly increased by TSH in parental (data not shown) and vector-transfected cells, but not in RasS35 cells (Figure 5c ). TSH retained the ability to increase NIS expression, albeit to slightly reduced levels, in RasC40 cells. The absence (RasS35) or reduced levels (RasC40) of NIS expression in the Ras-expressing cells were not due to aberrant localization since NIS expression was undetectable in cytosolic fractions prepared from TSH-treated cells (data not shown). Notably, NIS expression was similar in cells expressing RasC40 at threefold and 30-fold over cellular Ras (Figure 5c ), indicating that NIS expression is not progressively reduced by increasing levels of RasC40 expression. These results demonstrate that in marked contrast to the complete loss of thyroid-speci®c gene expression in RasS35 Figure 5 Expression of RasC40 is compatible with dierentiation. RasC40 cells were transferred to basal medium for 7 ± 10 days and thyroid-speci®c gene expression was examined in the absence (7TSH) or presence (+TSH) of 48 h treatment with TSH (1 mU/ ml). (a) Representative ®elds of vector-transfected (C) and RasC40 B3 cells are shown following immunostaining with an anti-Tg antibody. All photomicrographs were exposed for identical times. Tg expression was not detected in RasS35 cells by immunostaining (Miller et al., 1998) . Similar results were obtained in four experiments performed in RasC40 B3 cells, and in four experiments using RasC40 P6 cells. (b) Total cell lysates were analysed by immunoblotting with an anti-Tg antibody. Tg expression in RasC40 B3 cells (threefold overexpression; 36) or RasC40 P6 cells (30-fold overexpression; 306) did not dier from that in vector-transfected controls (C). Tg expression was not detected in cells overexpressing RasS35 by 30-fold (not shown). Similar results were obtained in ®ve experiments using RasC40 B3 cells, three experiments with RasC40 P6 cells, and in four experiments in RasS35 cells. (c) Membrane fractions were analysed by immunoblotting with an anti-NIS antibody. NIS expression in cells overexpressing RasC40 by threefold (36) and 30-fold (306) was increased by TSH, but to lesser levels than seen in vectortransfected control cells (C). Equal amounts of protein from each cell line was con®rmed by analysing Tg expression in the corresponding cytosolic fractions. NIS expression was not detected in cells overexpressing RasS35 by 30-fold. The broad band detected with the NIS antibody in WRT cells is virtually identical to that reported in FRTL-5 cells (Levy et al., 1997) . Similar results were obtained in four experiments using RasC40 B3 cells, two experiments with RasC40 P6 cells, and in three experiments in RasS35 cells cells, TSH retains the ability to induce the expression of thyroid-speci®c genes in RasC40 cells.
(448) Quiescent WRT cells were microinjected with RalGDS-RBD followed by 4 h treatment with TSH (1 mU/ml). Results are the mean+s.e.mean per cent of injected cells that exhibited S6 phosphorylation or BrdU incorporation. In each experiment, S6 phosphorylation and BrdU incorporation in control uninjected cells was also determined. The number of cells scored under each condition is indicated (N). IgG-injected cells are included as controls
Discussion
Like many hormones, TSH regulates proliferation and dierentiation in its target cell. Although the mitogenic activity of TSH is Ras-dependent (Kupperman et al., 1993) , oncogenic Ras impairs the ability of TSH to stimulate thyroid-speci®c gene expression. De-dierentiation occurs in Ras-transformed thyroid cells (Fusco et al., 1987; Avvedimento et al., 1989) and in cells acutely injected with Ras proteins (Kupperman et al., 1996) , indicating that even transient expression of activated Ras induces de-dierentiation. We sought to determine how Ras mediates the mitogenic eects of TSH in a manner that allows for maintenance of the dierentiated phenotype. Ras activates multiple downstream eectors including Raf-1, PI3K and RalGDS (Marshall, 1996; Campbell et al., 1998) . The contribution of individual Ras eectors to the inhibition of thyroid dierentiation has not been established. Crosstalk between cAMP and discrete Ras eectors, however, leads to dierential eects on thyroid cell proliferation. Acting through PKA, TSH transiently repressed Ras signaling to Raf-1 and Raf-1-mediated proliferation (Miller et al., 1998) . In contrast, activation of PI3K-dependent signals is required for the mitogenic eects of TSH (Cass et al., 1999) . Therefore, we examined whether Ras activation of PI3K was sucient to confer TSH-independent proliferation, and more importantly, if it could do so in cells that retained their dierentiated status.
Activation of PI3K following acute microinjection or stable expression of RasC40 conferred TSH-independent proliferation. Like that stimulated by TSH, RasC40-mediated proliferation was PI3K-and p70s6k-dependent and occurred in the absence of detectable MAPK activity. In striking contrast to its inhibitory eects on proliferation and MAPK activity in cells expressing RasS35 (Miller et al., 1998) , TSH modestly, but consistently enhanced RasC40-stimulated proliferation, an eect that was reproduced by cAMP elevating agents. The enhanced levels of DNA synthesis were accompanied by further activation of p70s6k, a crucial mediator of RasC40-and cAMPstimulated (Cass and Meinkoth, 1998) mitogenesis, suggesting that Ras and cAMP activate p70s6k through distinct signaling pathways. In support of this view, expression of RasN17 or microinjection of Rassequestering peptides had no eect on TSH-stimulated p70s6k activity in parental cells. Together with our ®ndings that TSH activates p70s6k through a PI3K-independent pathway (Cass et al., 1999) , these data indicate that TSH and Ras stimulate proliferation through discrete but interacting pathways.
The ability of RasC40 to confer TSH-independent proliferation supports earlier studies where RasC40 enhanced the proliferation of NIH3T3 ®broblasts in low serum (Khosravi-Far et al., 1996) . In contrast, RasC40 failed to stimulate cell cycle progression in REF52 ®broblasts (Joneson et al., 1996) or WT19 myeloid cells (Matsuguchi and Kraft, 1998) , suggesting that its mitogenic eects are cell type-dependent. In thyroid cells, the growth stimulatory eects of RasC40 were reproduced by expression of p110-CAAX (Cass et al., 1999) , a membrane-localized, constitutively active form of p110 . This veri®es that PI3K and its downstream targets, rather than an unidenti®ed eector, convey the mitogenic eects of RasC40. PI3K exhibits a well-established role in cell proliferation (Fantl et al., 1992; Kazlauskas et al., 1992; Roche et al., 1994; Jhun et al., 1994; Cheatham et al., 1994) . Acute or inducible expression of p110-CAAX stimulates growth factor-independent DNA synthesis in other cells (Klippel et al., 1998; Frevert and Kahn, 1997) . Expression of activated Rac1, a downstream eector of PI3K in the control of membrane ruing (Rodriguez-Viciana et al., 1997), failed to induce TSH-independent proliferation in FRTL-5 cells. However, similar to reports on ®broblast transformation (Khosravi-Far et al., 1995; Qiu et al., 1995; Rodriguez-Viciana et al., 1997) , co-expression of activated forms of Rac1 and MEK1 conferred TSHindependent DNA synthesis, although this eect was modest compared to that elicited by RasV12 . Together with our data, these results suggest that eectors in addition to Rac1 are required for PI3K-mediated proliferation in thyroid cells.
The most striking eect of RasC40 was its ability to confer TSH-independent proliferation in cells that retained their dierentiated status. TSH stimulated Tg expression in RasC40 cells to similar levels as in parental cells. NIS expression was also increased by TSH in RasC40 cells, albeit to slightly reduced levels compared to parental cells. Dierential eects on Tg and NIS expression were also observed following treatment with low doses of iodide (Uyttersprot et al., 1997) , suggesting that the expression of these proteins is regulated through distinct mechanisms. Interestingly, a recent report indicates that Pax-8, one of three thyroid-speci®c transcription factors , plays a prominent role in the regulation of NIS expression (Ohno et al., 1999) . Therefore, it is conceivable that RasC40-dependent signals impinge selectively upon Pax-8 expression and/or activity. The eects of Ras transformation on Pax-8 expression have not yet been reported, although reduced levels of Pax-8 expression have been observed in follicular adenomas (Heldin and Westermark, 1991) and in thyroid cells expressing mutated p53 (Battista et al., 1995) . RasC40-dependent signals might also downregulate the expression and/or activity of a recently described novel thyroid transcription factor involved in the regulation of NIS expression (Ohmori et al., 1998) , or could aect NIS activity through a post-transcriptional mechanism similar to that observed for TSH (Kaminsky et al., 1994) .
Strikingly, even when overexpressed 30-fold relative to cellular Ras, RasC40 failed to abolish Tg and NIS expression. Similarly, expression of p110-CAAX did not impair TSH eects on thyroid-speci®c gene expression. These ®ndings provide strong support that even chronic activation of PI3K is compatible with thyroid dierentiation. In addition, expression of activated Rac1 failed to impair dierentiation in FRTL-5 cells , further support that PI3K-dependent signals are compatible with thyroid dierentiation. PI3K activation is not compatible with all cAMPinduced dierentiation, however. In B16 melanoma cells, the eects of the cAMP-dependent hormone a-MSH on dierentiation are mediated through repression of PI3K activity, and inhibition of PI3K is sucient to stimulate melanin synthesis (Busca et al., 1996) . PI3K is also reported to negatively regulate the maturation of undierentiated fetal pancreatic islet cells (Ptasznik et al., 1997) . In many other cells, however, not only is PI3K required for dierentiation (Kimura et al., 1994; Cheatham et al., 1994; Okada et al., 1994; Kaliman et al., 1996) , but activation of PI3K or PI3K-dependent signals is sucient to induce markers of the dierentiated phenotype (Katagiri et al., 1996; Martin et al., 1996; Jiang et al., 1998; Kita et al., 1998) . Although PI3K is compatible with thyroid dierentiation, activation of PI3K is insucient to induce thyroid-speci®c gene expression. Additionally, concentrations of the PI3K inhibitor LY294002 that abolished TSH-stimulated DNA synthesis had no eect on thyroid-speci®c gene expression (Meinkoth, unpublished) . This is consistent with the observation that TSH-stimulated dierentiation is Ras-independent (Kupperman et al., 1996) . Based on these ®ndings, PI3K does not appear to be required for TSH eects on dierentiation.
The absence of inhibitory eects of RasC40 and PI3K on dierentiation stands in marked contrast to the eects observed in thyroid cells expressing RasV12 and RasS35, where Tg and NIS expression were abolished. RasV12 and RasS35 bind Raf-1 with higher anity than other Ras eectors , (Wittinghofer and Hermann, 1995) , suggesting that thyroid dedierentiation is mediated through Raf-1. Expression of activated MEK1, a downstream eector of Raf-1, alone or together with activated Rac1, did not impair FRTL-5 dierentiation . These results are reminiscent of those reported in C3H 10T1/2 cells where RasS35 and an activated form of Raf-1, but not MEK1, abolished myogenic dierentiation (Ramocki et al., 1997 (Ramocki et al., , 1998 . Therefore, the inability of MEK1 to impair dierentiation in FRTL-5 cells is not necessarily inconsistent with the inhibitory eects of RasS35 on Tg and NIS expression that we observed. Unlike RasS35, expression of RasG37, a mutant that binds preferentially to RalGDS, is compatible with the dierentiated phenotype (Miller et al., 1998) , and RalGDS is required for the mitogenic eects of TSH (Miller et al., 1997) . These results, together with the current studies in RasC40 cells are most consistent with the hypothesis that the inhibitory eects of Ras on thyroid dierentiation are Raf-1-, although not necessarily MEK1-, mediated. This is of particular interest since TSH selectively and uniquely impairs signaling through this particular Ras eector pathway.
Materials and methods
Reagents
Rapamycin, wortmannin and H89 were from Calbiochem. PD98059 was from New England BioLabs. FCS was from GIBCO Life Technologies. BSA was from Bayer Scienti®c. All other reagents including crude bovine TSH (1 U/ml), forskolin, 8BrcAMP, cholera toxin and insulin were from Sigma.
Cell culture
WRT cells were propagated in 3H medium (Coon's modi®ed Ham's F12 medium containing insulin (10 mg/ml), transferrin (5 mg/ml,) TSH (10 mU/ml), and 5% donor calf serum). Cells were rendered quiescent by starvation in basal medium (Coon's modi®ed Ham's F12 medium containing 0.3% BSA) for 24 ± 48 h. All experiments with wortmannin were conducted in BSA-free basal medium. Early passage cells were transfected with pDCR encoding hemagluttinin (HA)-tagged RasV12C40 or RasV12S35 (abbreviated RasC40 and RasS35), kindly provided by Dr M White (UTSW Medical Center). Ras-expressing cells were selected in 3H containing G418 (300 mg/ml). Clonal populations were established from individual drug-resistant colonies and pools were generated from mass populations of drug-resistant cells. Transfected cells were maintained in 3H containing G418 (150 mg/ml).
Adenoviral infection
WRT cells (1610 6 ) were plated in 60 mm dishes, transferred to basal medium, and infected with recombinant adenoviruses containing cDNA that encodes b-galactosidase (generously provided by Dr J Fox, Smith Kline Beecham) or dominant negative Ras (RasN17) and green¯uorescent protein (generously provided by Dr Virginia Lee, Department of Laboratory Medicine, University of Pennsylvania) at a multiplicity of infection (m.o.i.) of 10 and 25 plaque forming units (p.f.u.)/ml, respectively. After 5 h, cells were transfected to 3H medium for 16 h to allow for transgene expression, and then rendered quiescent as described above. Pilot studies using viruses encoding b-galactosidase and GFP revealed that more than 65% of the cells were productively infected.
Microinjection
GST fusion constructs encoding RasV12C40 or the Ras binding domain (RBD) of RalGDS (GST-RalGDS-RBD) were expressed and puri®ed from E. coli by anity chromatography (Miller et al., 1997) . The RasV12C40 protein was cleaved with thrombin to remove GST. Puri®ed RasV12C40 (0.1 ± 0.75 mg/ml) and GST-RalGDS-RBD (34.5 mg/ml) were injected into the cytoplasm together with IgG to identify injected cells. Based on an injection volume of 2610 714 I, the number of molecules injected per cell is approximately 28 000 to 215 000 (RasV12C40) and 7610 6 (GST-RalGDS-RBD).
DNA synthesis and S6 phosphorylation
RasC40 and RasS35 cells were plated in 3H for 16 h, transferred to basal medium for 48 h, and labeled with bromodeoxyuridine (BrdU) for 24 ± 48 h. In studies using TSH and cAMP elevating agents, basal medium was supplemented with insulin (0.5 mg/ml) to enhance the mitogenic eects of these agents. DNA synthesis was monitored by BrdU incorporation (LaMorte et al., 1992; Kupperman et al., 1993) . Inhibitors were added 2 h prior to BrdU addition. RasV12C40 protein was injected into quiescent WRT cells which were labeled with BrdU for 48 h post-injection. When included, inhibitors were added 10 min prior to injection. For S6 phosphorylation studies, V12RasC40-injected cells were ®xed at 24 h post-injection. Quiescent WRT cells injected with GST-RalGDS-RBD were treated with TSH at 8 h post-injection and ®xed 4 h later. Phosphorylated S6 was detected by immunostaining with an antibody raised to phosphorylated S6 protein (Cass et al., 1999) .
Immunoblotting
Cells plated in 3H for 16 h were transferred to basal medium for 24 h, stimulated with TSH for 0 ± 45 min, and lysed as previously described (Cass and Meinkoth, 1998) . When included, inhibitors were added 2 h prior to lysis. Protein concentrations were determined using the DC protein assay (Biorad, Hercules, CA, USA) and equal proteins were loaded for all treatments. Soluble proteins were denatured by boiling in Laemmli sample buer, resolved on 6.75% (p70s6k, phospho-Akt), 10% (phospho-MAPK) or 12.5% (phospho-S6, Ras) SDS ± PAGE, and transferred to polyvinylidenē uoride membranes. After blocking with PBS, 5% w/v milk, 0.1% Tween, membranes were incubated for 2 h with a monoclonal antibody to the HA epitope (provided by Dr J Field, Department of Pharmacology, University of Pennsylvania) or Ras (1 mg/ml; Oncogene OP41), or polyclonal antibodies raised to p70s6k (0.5 mg/ml; Santa Cruz sc-230), phospho-speci®c Akt-1 (Ser 473) (1 : 1000; New England Biolabs 9271), phospho-speci®c MAPK (Thr183/Tyr185) (1 : 1250; Promega V6671), or to a phosphorylated peptide of S6 (amino acids 232 ± 249; kindly provided by Dr M Birnbaum, HHMI, Department of Medicine, University of Pennsylvania), followed by incubation with HRP-conjugated anti-rabbit or anti-mouse antibodies (1 : 1000, Santa Cruz sc-2004 Cruz sc- , sc-2005 and detection using ECL (Amersham).
Thyroglobulin and NIS expression
Immunostaining for thyroglobulin expression was performed as previously described (Kupperman et al., 1996) . For Western blotting, cells were transferred to basal medium for 10 days and stimulated with TSH for 48 h. For Tg expression, soluble proteins were prepared as described above, and resolved on 6% SDS ± PAGE. For NIS expression, cells were scraped into ice-cold hypotonic lysis buer (20 mM HEPES pH 7.4, 2 mM MgCl 2 , 1 mM EDTA, 1 mM pefabloc, 10 mg/ml aprotonin and leupeptin) and lysates were homogenized by shearing through a 26G needle. Nuclei and unbroken cells were removed by centrifugation at 48C and 1000 g for 5 min, and the membrane fraction isolated by subsequent centrifugation at 100 000 g and 48C for 60 min. The membrane protein pellet was resuspended in lysis buer and resolved on 9% SDS ± PAGE. Transfer and blocking were performed as described above. Membranes were incubated overnight at 48C with a polyclonal antibody to thyroglobulin (1 : 800, Dako A251) or NIS (1 : 3000, kindly provided by Dr N Carrasco, Department of Molecular Pharmacology, Albert Einstein College of Medicine), followed by incubation with alkaline phosphatase-conjugated anti-rabbit antibody (1 : 1000 NEB 7051-1) and detection using CDP Star (NEB 7020).
